PE20040439A1 - Combinacion de compuestos organicos - Google Patents
Combinacion de compuestos organicosInfo
- Publication number
- PE20040439A1 PE20040439A1 PE2003000470A PE2003000470A PE20040439A1 PE 20040439 A1 PE20040439 A1 PE 20040439A1 PE 2003000470 A PE2003000470 A PE 2003000470A PE 2003000470 A PE2003000470 A PE 2003000470A PE 20040439 A1 PE20040439 A1 PE 20040439A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- organic compound
- compound combination
- composition
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229960004064 bumetanide Drugs 0.000 abstract 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 abstract 1
- 229960000932 candesartan Drugs 0.000 abstract 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 229960004563 eprosartan Drugs 0.000 abstract 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 abstract 1
- 229960003580 felodipine Drugs 0.000 abstract 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003883 furosemide Drugs 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract 1
- 229960002198 irbesartan Drugs 0.000 abstract 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004427 isradipine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38154702P | 2002-05-17 | 2002-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040439A1 true PE20040439A1 (es) | 2004-08-20 |
Family
ID=29550142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000470A PE20040439A1 (es) | 2002-05-17 | 2003-05-15 | Combinacion de compuestos organicos |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20050222137A1 (https=) |
| EP (1) | EP1507529B8 (https=) |
| JP (2) | JP5132872B2 (https=) |
| KR (2) | KR20050000546A (https=) |
| CN (2) | CN1652777A (https=) |
| AR (1) | AR040014A1 (https=) |
| AT (1) | ATE429223T1 (https=) |
| AU (1) | AU2003240261B2 (https=) |
| BR (1) | BR0310092A (https=) |
| CA (1) | CA2486144C (https=) |
| CY (1) | CY1109240T1 (https=) |
| DE (1) | DE60327316D1 (https=) |
| DK (1) | DK1507529T3 (https=) |
| EC (1) | ECSP045429A (https=) |
| EG (1) | EG24716A (https=) |
| ES (1) | ES2325207T3 (https=) |
| IL (1) | IL164925A (https=) |
| MX (1) | MXPA04011385A (https=) |
| MY (1) | MY138838A (https=) |
| NO (1) | NO333011B1 (https=) |
| NZ (1) | NZ536557A (https=) |
| PE (1) | PE20040439A1 (https=) |
| PL (1) | PL372369A1 (https=) |
| PT (1) | PT1507529E (https=) |
| RU (1) | RU2324482C2 (https=) |
| SI (1) | SI1507529T1 (https=) |
| TW (1) | TWI358291B (https=) |
| WO (1) | WO2003097045A1 (https=) |
| ZA (1) | ZA200408737B (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| MXPA05008142A (es) * | 2003-01-31 | 2005-09-30 | Sankyo Co | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension. |
| CA2525970C (en) | 2003-05-15 | 2011-03-22 | Roskamp Research, Llc | Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| US20070054947A1 (en) * | 2003-05-16 | 2007-03-08 | Cohn Jay N | Pharmaceutical composition comprising valsartan |
| JP2009513543A (ja) * | 2003-07-16 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | クロルタリドンの組み合わせ |
| GB0325605D0 (en) * | 2003-11-03 | 2003-12-10 | Novartis Ag | Combination of organic compounds |
| WO2005082329A2 (en) * | 2004-02-19 | 2005-09-09 | Ranbaxy Laboratories Limited | Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
| CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| JP4509118B2 (ja) * | 2004-10-06 | 2010-07-21 | エルメッド エーザイ株式会社 | 医薬組成物及びその製造方法、並びに医薬組成物におけるジヒドロピリジン系化合物の安定化方法 |
| CN103083318A (zh) * | 2004-11-05 | 2013-05-08 | 贝林格尔.英格海姆国际有限公司 | 包含替米沙坦和氨氯地平的双层片剂 |
| CN1830454A (zh) * | 2005-03-10 | 2006-09-13 | 刘智仁 | 盐酸在制备治疗高血压药物中的应用 |
| RU2420280C2 (ru) * | 2005-04-21 | 2011-06-10 | Сантен Фармасьютикал Ко., Лтд | Терапевтическое средство против кератоконъюнктивального расстройства |
| TWI407978B (zh) * | 2005-06-27 | 2013-09-11 | Sankyo Co | 濕粒狀藥物之製備方法 |
| CA2613417C (en) * | 2005-06-27 | 2011-11-29 | Daiichi Sankyo Company, Limited | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
| JP5110697B2 (ja) * | 2005-06-27 | 2012-12-26 | 第一三共株式会社 | 固形製剤 |
| DE102005031577A1 (de) | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| AU2007234380A1 (en) * | 2006-04-06 | 2007-10-11 | Novartis Ag | Combination of organic compounds |
| PE20080991A1 (es) * | 2006-06-27 | 2008-09-05 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| GB2471970A (en) * | 2006-09-15 | 2011-01-19 | Daiichi Sankyo Co Ltd | Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide |
| CN101199848B (zh) * | 2006-11-11 | 2012-05-23 | 深圳奥萨医药有限公司 | 钙通道阻滞剂/利尿剂/叶酸联用的药物组合物及其用途 |
| PL2106260T3 (pl) * | 2007-01-25 | 2018-06-29 | NAIA Metabolic, Inc. | Środki uwrażliwiające na insulinę i sposoby leczenia |
| GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
| TWI500422B (zh) | 2007-10-05 | 2015-09-21 | Alzheimer S Inst Of America Inc | 以（－）－尼代地平（ｎｉｌｖａｄｉｐｉｎｅ）對映異構物減低類澱粉沉積、類澱粉神經毒性及微神經膠細胞增生之方法 |
| JP2011507973A (ja) * | 2007-12-31 | 2011-03-10 | ルピン・リミテッド | アムロジピンとバルサルタンとの医薬組成物 |
| CN101564536B (zh) * | 2008-04-21 | 2010-12-15 | 鲁南制药集团股份有限公司 | 一种治疗高血压的药物组合物缓控释制剂 |
| US20100137403A1 (en) * | 2008-07-10 | 2010-06-03 | Scott Malstrom | Method for enhancing cognition or inhibiting cognitive decline |
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| MY173823A (en) | 2009-01-23 | 2020-02-24 | Hanmi Science Co Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
| RU2398581C1 (ru) * | 2009-05-28 | 2010-09-10 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс Федерального агентства по высокотехнологичной медицинской помощи (ФГУ РКНПК Росмедтехнологий) | Способ лечения больных гипертрофической кардиомиопатией |
| US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
| SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
| RU2425671C1 (ru) * | 2010-06-30 | 2011-08-10 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции нарушений функции почек у больных стабильной стенокардией в сочетании с гипертонической болезнью |
| TR201102067A1 (tr) | 2011-03-03 | 2012-09-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Valsartan ve amlodipin kombinasyonları. |
| GB201116993D0 (en) | 2011-10-03 | 2011-11-16 | Ems Sa | Pharmaceutical compositions of antihypertensives |
| KR101907881B1 (ko) * | 2011-12-30 | 2018-12-11 | 한미약품 주식회사 | 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형 |
| CA2872542A1 (en) | 2012-05-07 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil |
| WO2013191668A1 (en) | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
| MX358211B (es) * | 2012-07-23 | 2018-08-10 | Landsteiner Scient S A De C V | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. |
| US10918612B2 (en) * | 2013-01-22 | 2021-02-16 | Markus Zwickl | Combinations with 2-aminoethanesulfonic acid |
| EP3025711B1 (en) * | 2013-07-23 | 2020-11-18 | Daiichi Sankyo Company, Limited | Medicine for preventing or treating hypertension |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| CN104324377B (zh) * | 2014-06-19 | 2017-08-04 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
| KR101914930B1 (ko) * | 2015-03-31 | 2018-11-05 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제 |
| CN105106962A (zh) * | 2015-08-29 | 2015-12-02 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
| CN108778334A (zh) * | 2016-03-24 | 2018-11-09 | 第三共株式会社 | 用于治疗肾脏疾病的药物 |
| US10319209B2 (en) | 2016-06-03 | 2019-06-11 | John Carlton-Foss | Method and system for motion analysis and fall prevention |
| KR102912130B1 (ko) * | 2016-11-11 | 2026-01-14 | 주식회사유한양행 | 클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법 |
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US12521380B2 (en) | 2017-01-25 | 2026-01-13 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| KR20240096848A (ko) | 2017-01-25 | 2024-06-26 | 더 조지 인스티튜트 포 글로벌 헬스 | 고혈압의 치료를 위한 조성물 |
| KR102568472B1 (ko) | 2017-02-27 | 2023-08-18 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물 |
| KR20260037123A (ko) | 2017-11-30 | 2026-03-17 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용 |
| MX2021001043A (es) * | 2018-07-26 | 2021-04-12 | The George Inst For Global Health | Composiciones para el tratamiento de hipertension. |
| CN111789843A (zh) | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
| MX2022013029A (es) * | 2020-04-17 | 2023-01-16 | Honeybrains Llc | Composiciones y metodos para el tratamiento de trastornos neuropsiquiatricos. |
| US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
| GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
| KR102924710B1 (ko) | 2022-07-25 | 2026-02-09 | 안국약품 주식회사 | 암로디핀, 발사르탄 및 인다파미드를 포함하는 약학 제제 및 이의 제조 방법 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US5350771A (en) * | 1989-03-22 | 1994-09-27 | Peter K. T. Pang | Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers |
| EP0400835A1 (en) | 1989-05-15 | 1990-12-05 | Merck & Co. Inc. | Substituted benzimidazoles as angiotensin II antagonists |
| US5449682A (en) | 1990-02-13 | 1995-09-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted benzyl element |
| IL97219A (en) | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| AU656551B2 (en) * | 1990-12-14 | 1995-02-09 | Smithkline Beecham Corporation | Angiotensin II receptor blocking compositions |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| NZ242724A (en) * | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
| US5492904A (en) | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| US5260325A (en) | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
| US5202322A (en) | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| US5206348A (en) | 1992-07-23 | 1993-04-27 | Morton International, Inc. | Hexahydroxybenzophenone sulfonate esters of diazonaphthoquinone sensitizers and positive photoresists employing same |
| US5266583A (en) | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
| US5264447A (en) | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| US5721263A (en) | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2181461A1 (en) | 1994-02-08 | 1995-08-17 | Alica Huxley | Treatment of normotensive glaucoma with angiotensin ii antagonists |
| HUT76542A (en) | 1994-03-17 | 1997-09-29 | Ciba Geigy Ag | Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy |
| GB9406573D0 (en) | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
| AU726694B2 (en) | 1996-03-29 | 2000-11-16 | Smithkline Beecham Corporation | Eprosartan dihydrate and a process for its production and formulation |
| GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US5949290A (en) * | 1997-01-14 | 1999-09-07 | Bertram; Earnest L. | Voltage controlled oscillator tuning apparatus and method |
| JP2002503223A (ja) | 1997-04-11 | 2002-01-29 | アドバンスト・メディシン・インコーポレイテッド | 複数の活性分子を供与する分子 |
| US5991348A (en) * | 1997-08-12 | 1999-11-23 | 3Com Corporation | Method and apparatus for regenerating symbol timing from a probing signal in a system having non-linear network and codec distortion |
| DE19820151A1 (de) * | 1998-05-06 | 1999-11-11 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Candesartan |
| NZ509260A (en) * | 1998-07-10 | 2003-09-26 | Novartis Ag | Pharmaceutical composition containing valsartan and a calcium channel blocker |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| ATE524176T1 (de) | 1998-12-23 | 2011-09-15 | Novartis Pharma Gmbh | Valsartan tablette |
| JP2002535367A (ja) | 1999-01-26 | 2002-10-22 | ノバルティス アクチエンゲゼルシャフト | 急性心筋梗塞の処置のためのアンギオテンシンｉｉレセプターアンタゴニストの使用 |
| US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| CN1301545A (zh) | 1999-12-27 | 2001-07-04 | 王德山 | 一种复方降血压药 |
| DE10004651A1 (de) * | 2000-02-03 | 2001-08-16 | Jutta Dierkes | Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen |
| BR0112665A (pt) | 2000-07-19 | 2003-06-24 | Novartis Ag | Sais |
| US20040087484A1 (en) | 2000-12-01 | 2004-05-06 | Sahota Pritam Singh | Combination of organic compounds |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas |
-
2003
- 2003-05-14 EG EG2003050449A patent/EG24716A/xx active
- 2003-05-15 AR ARP030101691A patent/AR040014A1/es unknown
- 2003-05-15 TW TW092113236A patent/TWI358291B/zh not_active IP Right Cessation
- 2003-05-15 PE PE2003000470A patent/PE20040439A1/es not_active Application Discontinuation
- 2003-05-16 RU RU2004137105/15A patent/RU2324482C2/ru not_active IP Right Cessation
- 2003-05-16 KR KR10-2004-7018461A patent/KR20050000546A/ko not_active Ceased
- 2003-05-16 SI SI200331623T patent/SI1507529T1/sl unknown
- 2003-05-16 JP JP2004505044A patent/JP5132872B2/ja not_active Expired - Lifetime
- 2003-05-16 CN CNA038112442A patent/CN1652777A/zh active Pending
- 2003-05-16 DK DK03732397T patent/DK1507529T3/da active
- 2003-05-16 MY MYPI20031827A patent/MY138838A/en unknown
- 2003-05-16 CA CA2486144A patent/CA2486144C/en not_active Expired - Lifetime
- 2003-05-16 NZ NZ536557A patent/NZ536557A/en not_active IP Right Cessation
- 2003-05-16 US US10/514,682 patent/US20050222137A1/en not_active Abandoned
- 2003-05-16 AU AU2003240261A patent/AU2003240261B2/en not_active Expired
- 2003-05-16 MX MXPA04011385A patent/MXPA04011385A/es active IP Right Grant
- 2003-05-16 CN CN2009102075232A patent/CN101890166A/zh active Pending
- 2003-05-16 PL PL03372369A patent/PL372369A1/xx not_active Application Discontinuation
- 2003-05-16 WO PCT/EP2003/005180 patent/WO2003097045A1/en not_active Ceased
- 2003-05-16 EP EP03732397A patent/EP1507529B8/en not_active Revoked
- 2003-05-16 AT AT03732397T patent/ATE429223T1/de active
- 2003-05-16 DE DE60327316T patent/DE60327316D1/de not_active Expired - Lifetime
- 2003-05-16 PT PT03732397T patent/PT1507529E/pt unknown
- 2003-05-16 ES ES03732397T patent/ES2325207T3/es not_active Expired - Lifetime
- 2003-05-16 KR KR1020117021915A patent/KR101454070B1/ko not_active Expired - Lifetime
- 2003-05-16 BR BR0310092-8A patent/BR0310092A/pt not_active Application Discontinuation
-
2004
- 2004-10-28 ZA ZA200408737A patent/ZA200408737B/en unknown
- 2004-10-28 IL IL164925A patent/IL164925A/en unknown
- 2004-11-12 EC EC2004005429A patent/ECSP045429A/es unknown
- 2004-12-13 NO NO20045429A patent/NO333011B1/no not_active IP Right Cessation
-
2008
- 2008-12-18 US US12/338,066 patent/US8101599B2/en not_active Expired - Fee Related
-
2009
- 2009-07-14 CY CY20091100746T patent/CY1109240T1/el unknown
-
2010
- 2010-07-02 JP JP2010152053A patent/JP2010209123A/ja active Pending
-
2012
- 2012-01-12 US US13/348,833 patent/US20120115854A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040439A1 (es) | Combinacion de compuestos organicos | |
| PE20040468A1 (es) | Combinacion de compuestos organicos | |
| JP5148296B2 (ja) | アンジオテンシンｉｉ受容体拮抗剤及びカルシウム拮抗剤含有医薬組成物 | |
| JP5110697B2 (ja) | 固形製剤 | |
| JP5063370B2 (ja) | 湿式造粒製薬の調製方法 | |
| RU2019126749A (ru) | Композиции для лечения гипертензии | |
| PE20050464A1 (es) | Formulacion farmaceutica de la sal sodica del telmisartan | |
| PE107099A1 (es) | Composicion de atorvastatina y un antihipertensor | |
| PE20010940A1 (es) | Composiciones de valdecoxib | |
| CL2004000643A1 (es) | Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana. | |
| JP2005533023A5 (https=) | ||
| EP1575566A4 (en) | MULTILAYER DOSAGE FORMS WITH NSAIDS AND TRIPTANES | |
| CA2568640A1 (en) | Pharmaceutical composition containing irbesartan | |
| TR200101470T2 (tr) | Farmasötik bileşim terkipleri. | |
| JP2020506180A5 (https=) | ||
| PE20000066A1 (es) | Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion | |
| BR0111868A (pt) | Composições farmacêuticas | |
| HRP20120134T1 (hr) | Stabilni i lako topivljivi pripravci kandesartan-cileksetila, dobiveni vlažnim granuliranjem | |
| WO2002098850A3 (en) | Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors | |
| WO2004108084A3 (en) | Polymorphic forms of naltrexone | |
| EP1549655A4 (en) | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS | |
| ATE390148T1 (de) | Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker | |
| PE20050252A1 (es) | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+ | |
| BRPI0503775A (pt) | composição que compreende um amido parcialmente pré-gelatinizado e método de preparar o mesmo | |
| JP6532984B2 (ja) | 高血圧症の予防又は治療のための併用医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |